{"id":44566,"date":"2025-10-27T21:05:36","date_gmt":"2025-10-27T13:05:36","guid":{"rendered":"https:\/\/flcube.com\/?p=44566"},"modified":"2025-10-27T21:05:38","modified_gmt":"2025-10-27T13:05:38","slug":"zhifeis-ca111-injection-approved-for-clinical-trials-targeting-weight-loss-and-hypoglycemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44566","title":{"rendered":"Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia"},"content":{"rendered":"\n

Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122<\/a>) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly’s tirzepatide.<\/p>\n\n\n\n

Drug Mechanism and Advantages<\/strong>
CA111 is a dual agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-target design offers synergistic mechanisms, providing superior efficacy in lowering blood sugar and reducing body weight while minimizing side effects. Currently, Eli Lilly’s tirzepatide Injection is the only approved GIP\/GLP-1 dual agonist, with no domestic equivalents available in China.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received…<\/p>\n","protected":false},"author":1,"featured_media":44567,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[3892,62,39,86,879,878],"class_list":["post-44566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chenan-biopharmaceutical","tag-clinical-trial-approval-initiation","tag-diabetes","tag-obesity","tag-she-300122","tag-zhifei-biological"],"yoast_head":"\nZhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Zhifei Biological Co., Ltd's (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China's National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly's tirzepatide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44566\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia\" \/>\n<meta property=\"og:description\" content=\"Chongqing Zhifei Biological Co., Ltd's (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China's National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly's tirzepatide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44566\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T13:05:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T13:05:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1079\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia\",\"datePublished\":\"2025-10-27T13:05:36+00:00\",\"dateModified\":\"2025-10-27T13:05:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566\"},\"wordCount\":131,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2702.webp\",\"keywords\":[\"Chenan Biopharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"Obesity\",\"SHE: 300122\",\"Zhifei Biological\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44566#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44566\",\"name\":\"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2702.webp\",\"datePublished\":\"2025-10-27T13:05:36+00:00\",\"dateModified\":\"2025-10-27T13:05:38+00:00\",\"description\":\"Chongqing Zhifei Biological Co., Ltd's (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China's National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly's tirzepatide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44566\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2702.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2702.webp\",\"width\":1079,\"height\":608,\"caption\":\"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44566#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia - Insight, China's Pharmaceutical Industry","description":"Chongqing Zhifei Biological Co., Ltd's (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China's National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly's tirzepatide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44566","og_locale":"en_US","og_type":"article","og_title":"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia","og_description":"Chongqing Zhifei Biological Co., Ltd's (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China's National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly's tirzepatide.","og_url":"https:\/\/flcube.com\/?p=44566","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-27T13:05:36+00:00","article_modified_time":"2025-10-27T13:05:38+00:00","og_image":[{"width":1079,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44566#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44566"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia","datePublished":"2025-10-27T13:05:36+00:00","dateModified":"2025-10-27T13:05:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44566"},"wordCount":131,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44566#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp","keywords":["Chenan Biopharmaceutical","Clinical trial approval \/ initiation","Diabetes","Obesity","SHE: 300122","Zhifei Biological"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44566#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44566","url":"https:\/\/flcube.com\/?p=44566","name":"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44566#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44566#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp","datePublished":"2025-10-27T13:05:36+00:00","dateModified":"2025-10-27T13:05:38+00:00","description":"Chongqing Zhifei Biological Co., Ltd's (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China's National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly's tirzepatide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44566#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44566"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44566#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp","width":1079,"height":608,"caption":"Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44566#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2702.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44566"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44566\/revisions"}],"predecessor-version":[{"id":44568,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44566\/revisions\/44568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44567"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}